Novo Nordisk stock falls as 2026 plan targets peer growth

Novo Nordisk told investors in London on 21 September 2026 that it aims to grow revenue in line with 14 industry peers between 2026 and 2030.

The same morning, its CagriSema injection beat a low dose of Eli Lilly’s tirzepatide on weight loss in a Phase 3 trial, Novo’s trial release showed. US-listed shares still traded 4.3% below their 18 September close before the opening bell, StockAnalysis data showed.

For shareholders, the Capital Markets Day carried more weight than the trial result. The next test comes in the fourth quarter of 2026, when the US Food and Drug Administration is due to rule on CagriSema for weight management.

Novo’s 2030 ambitions stop short of formal guidance

Novo aims to launch more than five multi-blockbuster drugs by 2030 and reach more than 150 billion Danish kroner in pipeline sales in 2035, the Capital Markets Day release stated.

That pipeline figure is risk-adjusted and includes current assets, a footnote to the release noted. At 6.507 kroner to the dollar on 21 September 2026, it converts to about $23.1 billion, based on Investing.com rate data.

The same footnote said every ambition runs from a 2026 baseline, relies on adjusted metrics and does not constitute financial outlook or guidance. The release did not address buybacks, cost programs, US pricing or the company’s 2026 outlook.

More News on Finance Tracked:

• Buffett seals the end of an era at Berkshire
• J&J offloads $400M Laminar bet and exits LAA closure

Peer-level growth leaves Novo at a quarter of Lilly’s earnings multiple

The release names 14 industry peers, running from Eli Lilly and AstraZeneca to Pfizer and Bristol Myers Squibb. Novo also committed to a broadly stable operating margin and an attractive dividend per share through 2030, the release showed.

Matching that broad peer group implies slower growth than investors have historically come to expect from Novo, Jacob Pedersen, investment strategist at Middelfart Sparekasse, told CNBC.

“The investors, they are very particular in what they want from Novo, and this doesn’t add up to it.” — Jacob Pedersen, investment strategist, Middelfart Sparekasse, speaking to CNBC

In Pedersen’s reading, the stable-margin pledge still fell short of the financial ambition the market wanted to see from the Danish drugmaker, CNBC reported.

How Novo’s multiple compares with Lilly’s

Novo traded at about 10.4 times its trailing earnings per share of $4.00, based on the premarket price and StockAnalysis figures. Eli Lilly closed 18 September at 38.7 times trailing earnings, nearly four times Novo’s multiple, StockAnalysis data showed.

On forward estimates, the gap narrows to about 13.8 times for Novo against 28.3 times for Lilly. Novo’s forward multiple sits above its trailing one, which signals that analysts expect its earnings to shrink.

Key Novo figures from 21 September 2026

• Pipeline sales ambition: more than 150 billion kroner, about $23.1 billion, in 2035 on a risk-adjusted basis (Capital Markets Day release)
• Revenue ambition: 2026 to 2030 compound annual growth in line with 14 named peers, on an adjusted basis (Capital Markets Day release)
• Launch target: more than five multi-blockbusters by 2030 (Capital Markets Day release)
• REIMAGINE 5 weight loss: 12.4% for CagriSema against 9.1% for tirzepatide at 60 weeks, efficacy estimand (trial release)
• Share price: down 4.3% before the Sept. 21 market open from the $43.24 close on Sept. 18 (StockAnalysis) 
• Market value: about $183 billion at the premarket price, roughly $8 billion below the $191.0 billion close (StockAnalysis)

CagriSema’s win over tirzepatide came at lower doses of both drugs

REIMAGINE 5 enrolled adults with type 2 diabetes whose blood sugar was not controlled on metformin, an SGLT2 inhibitor or both. Over 60 weeks, CagriSema 1.0 mg/1.0 mg cut body weight by 12.4% against 9.1% for tirzepatide 5 mg, the trial results showed.

CagriSema also proved non-inferior on blood sugar, lowering HbA1c by 1.71 percentage points against 1.67 for tirzepatide. Novo said the drug was well tolerated overall, with a safety profile consistent with earlier studies.

“With only 1.0 mg/1.0 mg, CagriSema shows superior weight loss versus tirzepatide 5 mg as well as strong results across obesity and type 2 diabetes.” — Martin Holst Lange, executive vice president of Research & Development and chief scientific officer, Novo, in the company’s trial release

Lange tied the result to the 1.0 mg/1.0 mg dose and, in the same statement, described CagriSema as a product that remains investigational.

What the lower-dose result leaves unanswered

Neither arm in REIMAGINE 5 used the top dose of its drug. In the REDEFINE 4 trial in February, CagriSema 2.4 mg produced 23% weight loss at 84 weeks, compared with 25.5% for tirzepatide 15 mg, and missed non-inferiority, CNBC reported.

Novo argued that not all patients receive or stay on the highest available dose, so lower-dose evidence can inform individualized care. The weight-loss figures Novo released use the efficacy estimand, which tracks patients who stay on treatment as planned.

The release did not report treatment-regimen estimand results, which assess treatment effect regardless of treatment adherence.

REDEFINE 9 and the FDA timeline

In REDEFINE 9, the 1.0 mg/1.0 mg dose delivered 21.0% weight loss at 68 weeks versus 2.0% for placebo. The trial also included a 1.7 mg/1.7 mg dose, but Novo did not report a weight-loss result for that dose in the Sept. 21 release.

Novo filed its New Drug Application for CagriSema in weight management in December 2025 and expects an FDA decision in the fourth quarter of 2026, the release stated.

The bull case rests on a 3.1% yield and a risk-adjusted pipeline

Novo’s $1.28 annual dividend equals a yield of about 3.1% at the premarket price, with a payout ratio near 32%, StockAnalysis data showed. The Capital Markets Day commitments put that dividend and a stable margin on the record through 2030.

Second-quarter 2026 adjusted sales rose 7% at constant exchange rates, while adjusted operating profit rose 11%, TIKR reported.

The 150 billion kroner target already carries a risk adjustment, so it does not assume that every program in the pipeline succeeds. Delivering peer-level growth from about 10 times earnings would leave room for the multiple to rise, since Lilly, one of the 14 named peers, trades near 39 times.

The bear case starts with a 2026 base that is shrinking

Novo said in its Aug. 4 financial update that 2026 adjusted sales and operating profit are expected to decline between 0% and -6% at constant exchange rates. Because the 2030 ambitions start from that 2026 baseline, peer-level growth would compound from a smaller base.

CagriSema’s trial record adds to the caution, because Novo’s Copenhagen shares closed down 16.5% at 251 kroner after REDEFINE 4 missed in February, CNBC reported.

“Investors hoped for a project ‘miracle’ that could turn the momentum around short term. For obvious reasons that miracle does not exist.” — Per Hansen, savings economist, Nordnet, speaking to CNBC

Hansen’s point is that investors wanted a short-term turnaround, and targets set for 2030 and 2035 do not supply one.

Competition and patent pressure on semaglutide

Lilly has captured more than 30% of new US patients on oral weight-loss drugs with its Foundayo pill, Reuters reported on 14 September 2026.

Morgan Stanley cut Novo to Underweight earlier in September with a $40 price target and cited patent risk for semaglutide, the ingredient in Wegovy and Ozempic, Stocktwits reported.

The discount looks earned until CagriSema clears the FDA

On the figures available on 21 September, Novo’s share price matches the business it described in London. Analysts tracked by StockAnalysis forecast about 1.4% annual revenue growth over three years. 

The pipeline is where the market could be underpricing Novo, but most of the 2035 value rests on launches that have not happened. A narrower discount would need approvals first, and the fourth-quarter FDA ruling on CagriSema is the earliest one on the calendar.

An approval would give early support to the 2030 launch count and the pipeline case built around it. A delay or a restrictive label would push that case further out and leave the stock priced as the ex-growth pharma it now describes.

What Novo’s 2030 reset means for Novo Nordisk shareholders

Novo has recast itself as a peer-growth drugmaker with a stable margin and a dividend commitment, and the market priced it near 10 times trailing earnings on 21 September. That price leaves the pipeline behind Novo’s multi-blockbuster target unproven in investors’ eyes until approvals arrive.

Two dates on the calendar will test whether investors have priced the reset correctly. The FDA decision on CagriSema is due in the fourth quarter of 2026, and Novo reports first-nine-month results on 4 November 2026.